Astrin Aims for Mainstream with Certitude Breast Cancer Test
Astrin Biosciences is expanding physician outreach and preparing a direct-to-consumer launch for Certitude, a proteomic-based breast cancer diagnostic test that leverages mass spectrometry and machine learning. According to the company, the test identifies high-risk patients and detects early-stage malignancies from a small plasma sample. How Proteomics and AI Outperform Traditional DNA Liquid Biopsies in Early … Read more